Email : info@otcjournal.com
URL : http://www.otcjournal.com
To
OTC Journal Members:
 |
Special
Announcement- Must Read Weekend Edition |
 |
This weekend's edition will be a
must read for all stock market investors. Dr. Richard Geist,
considered to be today's foremost authority on the psychology of investing,
has written an article exclusively for members of the OTC Journal on
the psychological aspects of dealing with the worst Bear Market in history.
Dr. Richard Geist has a Ph.D.
in psychology from Harvard. He has published numerous works on the
psychology of investing, is a frequent guest on CNN, CNBC, Bloomberg, and
all the major television networks devoted to the stock market. He is often
quoted in major publication including the NY Times, Wall Street Journal,
Barron's, and Forbes.
Dr. Geist publishes his own
newsletter entitled Strategic Investing. He is a long time
devotee of small and microcap stocks, and is an avid investor. He suffers
the same psychological stress we all have felt in this environment. We
have seen the first draft of this weekend's edition, and there are some
outstanding observations which you will find striking. There are also some
concrete suggestions for renewing your enthusiasm for the market. This
edition is a must read for all investors.
 |
Calypte Biomed
(OTC BB: CALY)- News Before the Open Kicks Stock Higher |
|
Calypte Biomed is holding
it's June quarterly results conference call at 11:000 AM EST this morning.
In advance of the call the company issued a press release today which is
reversing the recent pull back in the stock, and could take the stock much
higher.
Calypte is the only company
with an FDA Approval on a urine based HIV test kit, substantially
less costly than the more prevalent blood test. It has been adopted by
many major US insurance companies, but a far larger market for this product
exists internationally where the spread of the HIV virus has reached crisis
proportions.
If you are considering investing
in this stock or adding to an existing position, technical indicators in
the depicted chart suggest an ideal entry point. After making a 300%
run in three weeks beginning in late June, the stock has given
back more than half of those gains. It has pulled back exactly to its support
line as shown in blue, back to the 50 day
moving average shown in yellow, and back to
the 200 day moving average shown in red.
Market technicians will tell you
this stock is poised to move. A move to the upside confirms the up trend
remains intact, and the stock has a high probability of regaining at least
half of its previous high. This would put Calypte back to about
the $.33 level, 50% above yesterday's closing price.
Today's news, which came out just
before the market opened, bodes well for Calypte's planned penetration
of the international market for its revolutionary test kit.
Calypte announced the World
Health Organization has complete Phase 1 testing of its urine based
HIV test kit. The World Health Organization will now commence Phase II,
the final phase required for approval.
Final approval will be a significant
milestone for Calypte. For a test of this type, the approval of
the World Health Organization has much greater impact than the existing
FDA Approval.
An approval from the World Health
Organization is the equivalent of an FDA Approval for many third world
countries that don't have their own testing government agencies. They simply
adopt World Health Organization approvals.
More importantly, once approval
is granted, third world countries can order test kits, and the World Health
Organization provides the money for purchases on behalf to these
beleaguered nations.
It is estimated there are less than
one million people infected with the HIV virus in North America. However,
this epidemic is raging in Africa and Asia, where it is estimated there
are more than 14 million people and more than 5 million people
respectively carrying and spreading the HIV virus.
Common sense would suggest in order
to stop the spread of AIDS, you have to identify who has it. Calypte
has the least expensive and most reliable method for testing available
in the world today. Final approval from the World Health Organization could
yield substantial revenues for Calypte.
This company already has a fairly
large and active following, and it has already traded more than 1
million shares as we write this addition, just one hour into the
trading day.
A good short term target of $.33
would be realistic for short term investors (one to three months). Longer
term, shareholders could realize much more substantial gains if the company
is successful in penetrating the international market where demand is enormous.
Here is the complete text of the
news release for your review:
Thursday July 25, 9:00 am Eastern
Time
Press Release
SOURCE: Calypte Biomedical Corp.
World Health Organization Completes
Phase One Evaluations of Three Calypte Urine HIV Tests: Second and Final
Phase of Testing Set to Commence
ALAMEDA, Calif.--(BW HealthWire)--July
25, 2002--Calypte Biomedical Corporation (OTCBB:CALY - News) announced
today that the World Health Organization (WHO) has completed Phase One
evaluations of three Calypte HIV-1 Urine tests. The evaluations were carried
out at the WHO's collaborating laboratory at the Institute of Tropical
Diseases in Antwerp, Belgium.
Two of the tests evaluated are already
USFDA-cleared HIV-1 antibody tests, one being a screening EIA and the other,
a supplementary Western Blot. The third test that was evaluated is a modified
version of the screening EIA which is currently marketed only outside the
United States. All three tests will undergo a second and final phase of
testing at a limited number of remote sites chosen by the WHO.
The detailed results of the Phase
One evaluations are expected to be released by the WHO internally, as well
as publicly on the WHO's official Web site (http://www.who.int). Calypte
believes that successful evaluation of its tests by the WHO is an important
step in making its urine-based HIV tests more accessible to the developing
world.
According to Nancy Katz, President
and CEO of Calypte, "The WHO is, in and of itself, an important consumer
of HIV tests. Moreover, since many developing countries closely model their
HIV testing policies upon WHO guidelines, inclusion of the urine testing
option in those guidelines is an extremely important goal for Calypte.
"We were very pleased with the thorough
and professional manner in which these evaluations were performed, and
we look forward to continued cooperation with the WHO as we make new tests
available," concluded Ms. Katz.
Calypte Biomedical Corporation, headquartered
in Alameda, California, is a public healthcare company dedicated to the
development and commercialization of urine-based diagnostic products and
services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted
diseases and other infectious diseases. Calypte's tests include the screening
EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1
antibody tests that can be used on urine samples. The company believes
that accurate, non-invasive urine-based testing methods for HIV and other
infectious diseases may make important contributions to public health by
helping to foster an environment in which testing may be done safely, economically,
and painlessly. Calypte markets its products in countries worldwide through
international distributors and strategic partners. Current product labeling
including specific product performance claims can be found on our Web site
at www.calypte.com.
Statements in this press release
that are not historical facts are forward-looking statements, including
statements regarding the status of Calypte products with the WHO, and any
potential impact that WHO status may have upon the Company's revenue opportunities
in international markets. Such statements reflect management's current
views, are based on certain assumptions and involve risks and uncertainties.
Actual results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will
be dependent upon a variety of factors, including, but not limited to,
our ability to obtain additional financing that will allow us to continue
our current and future operations and whether demand for our product and
testing service in domestic and international markets will continue to
expand. The Company undertakes no obligation to publicly update these forward-looking
statements to reflect events or circumstances that occur after the date
hereof or to reflect any change in the Company's expectations with regard
to these forward-looking statements or the occurrence of unanticipated
events. Factors that may impact the Company's success are more fully disclosed
in the Company's most recent public filings with the U.S. Securities and
Exchange Commission ("SEC"), including its annual report on Form 10-K for
the year ended December 31, 2000, and its subsequent filings with the SEC.
--------------------------------------------------------------------------------
Contact:
Calypte
Biomedical Corp., Alameda
Richard
Van Maanen, 510/749-5153
www.calypte.com
|
Charts Provided Courtesy
Of TradePortal.com
The OTC Journal is
a proud partner of the SwingWire.com
Online Investment Community. A next generation Online Analyst Exchange
providing Members the ability to search, review, track and monitor some
of the Internet's best Online CAs (CyberAnalysts). Members
have the opportunity to potentially achieve higher
returns by viewing top performing portfolios
and receiving real-time alerts from favorite CAs.
SwingWire.com
also has a lucrative incentive model for experienced investors and traders
who consistently outperform the market. Share market ideas with other like-minded
investors, establish a proven track record, provide insightful commentary,
attract followers and ultimately become one of the Internet's highest paid
and most sought after CyberAnalysts!
Click
here to receive your FREE 30-Day Trial Membership with no further obligation.
Sign Up Today!
|
